Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
30.09%
Operating Margin
22.29%
Net Margin
9.17%
Efficiency Metrics
Revenue per Expense Ratio
1.24
R&D as % of Revenue
0.36%
Earnings Quality
EBITDA Margin
39.55%
Income Tax Rate
29.97%
EPS
2.2800000000
Balance Sheet Analysis
Current Ratio
0.60
Cash Ratio
0.15
Working Capital
$-4.84B
Debt to Equity
1.79
Debt to Assets
50.29%
Equity Ratio
28.12%
Cash Flow Analysis
Operating Cash Flow Ratio
32.21%
Free Cash Flow Ratio
12.90%
CapEx to Revenue
19.31%
Dividends Paid
$3.67B
Stock Buybacks
$363.00M
Total Shareholder Returns
$4.03B
Cash Position Change
418.12%
Key Takeaways (2023 FY)
Increased dividend payments by 6.30%
Increased R&D investment by 57.89%
Detailed Growth Metrics
Core Performance
Revenue
2.06%
Net Income
-21.09%
EPS
-23.49%
Operating Income
1.61%
Operational Efficiency
R&D Expenses
57.89%
SG&A Expenses
-58.48%
Operating Cash Flow
-5.01%
Free Cash Flow
-1.46%
Balance Sheet Health
Assets
3.77%
Debt
13.34%
Book Value per Share
-8.77%
Inventory
-29.12%
Shareholder Returns
Dividends per Share
6.30%
Shares Outstanding
0.08%
Long Term Trends
3Y Revenue/Share
6.89%
5Y Revenue/Share
3.57%
3Y Dividend/Share
17.03%
5Y Dividend/Share
27.77%